Concurrent use of selected agents with moxifloxacin: An examination of labeling compliance within 1 year of marketing

Archives of Internal Medicine

Volumn 162, Issue 17, 2002, Pages 2011-2012

  Brinker, Allen ^a   Staffa, Judy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; LEVOFLOXACIN; MOXIFLOXACIN; PROCAINAMIDE; QUINIDINE; SOTALOL;

DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; LONG QT SYNDROME; NOTE; PRIORITY JOURNAL; QT INTERVAL; STATISTICAL ANALYSIS; UNITED STATES;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CLINICAL TRIALS; DRUG LABELING; FLUOROQUINOLONES; GUIDELINE ADHERENCE; HUMANS; OFLOXACIN; PRODUCT SURVEILLANCE, POSTMARKETING; QUINOLINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037163460     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.17.2011     Document Type: Note

References (5)

1. Avelox. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 2001:839-843.
2. Iannini PB, Kubin R, Reiter C, Tillotson G. Reassuring the safety profile of moxifloxacin [letter]. Clin Infect Dis. 2001;32:1112-1114.
3. White CM, Grant EM, Quintiliani R. Moxifloxacin does increase the corrected QT interval [letter]. Clin Infect Dis. 2001;33:1441-1444.
4. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21:1468-1472.
5. Levaquin. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 2001: 2338-2344.